Effects of clobenpropit (VUF-9153), a histamine H3-receptor antagonist, on learning and memory, and on cholinergic and monoaminergic systems in mice

Life Sciences

Volumn 61, Issue 4, 1997, Pages 355-361

  Miyazaki, Shuichi ^a   Onodera, Kenji ^b   Imaizumi, Masahiro ^a   Timmerman, Hendrik ^c  

^a YAMASA CORPORATION   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Clobenpropit; Histamine; Histamine H3 receptor; Learning; Memory; Passive avoidance test

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; ACETYLCHOLINE; ALPHA METHYLHISTAMINE; CHOLINE; CLOBENPROPIT; HISTAMINE H1 RECEPTOR; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; HOMOVANILLIC ACID; MEPYRAMINE; MONOAMINE; NORADRENALIN; SCOPOLAMINE; SEROTONIN; ZOLANTIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DIENCEPHALON; INTRAPERITONEAL DRUG ADMINISTRATION; LEARNING DISORDER; MALE; MEDULLA OBLONGATA; MEMORY; MESENCEPHALON; MONOAMINERGIC SYSTEM; MOUSE; NONHUMAN; PASSIVE AVOIDANCE; PONS;

ACETYLCHOLINE; ANIMALS; AVOIDANCE LEARNING; BENZOTHIAZOLES; BIOGENIC MONOAMINES; BRAIN; DRUG INTERACTIONS; HISTAMINE ANTAGONISTS; HISTAMINE H2 ANTAGONISTS; IMIDAZOLES; MALE; MEMORY; METHYLHISTAMINES; MICE; MICE, INBRED ICR; PHENOXYPROPANOLAMINES; PIPERIDINES; PYRILAMINE; RECEPTORS, HISTAMINE H1; RECEPTORS, HISTAMINE H3; SCOPOLAMINE; THIAZOLES; THIOUREA;

ANIMALIA;

EID: 0030849712     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(97)00406-2     Document Type: Article

References (33)

1. J.M. ARRANG, M. GARBARG and J.C. SCHWARTZ, Nature 302 832-837 (1983).
2. J.M. ARRANG, M. GARBARG and J.C. SCHWARTZ, Neurosci. 15 553-562 (1985).
3. J.M. ARRANG, M. GARBARG J.C. LANCELOT, J.M. LECOMT, H. POLLARD, M. ROBBA, W. SCHUNACK and J.C. SCHWARTZ, Nature 327 117-123 (1987).
4. C.E. TEDFORD, S.L. YATES, G.P. PAULOWSKI, J.W. NALWALK, L.B. HOUGH, M.A. KHAN, G.J. DURANT and R.E.A. FREDERICKSON, J. Pharmacol. Exp. Ther. 275 598-604 (1995).
5. H. VAN DER GOOT, M.J.P. SCHEPERS, G.J. STERK and H. TIMMERMAN, Eur. J. Med. Chem. 27 511-517 (1992).
6. R. LEURS and H. TIMMERMAN, Prog. Drug Res. 39 127-165 (1992).
7. X. LIGNEAU, M. GARBARG, M.L. VIZUETE, J. DIAZ, K. PURAND, H. STARK, W. SCHUNACK and J.C. SCHWARTZ, J. Pharmacol. Exp. Ther. 271 452-459 (1994).
8. R. LEURS, M.Th.M. TULP, W.M.B.P. MENGE, M.J.P. ADOLFS, O.P. ZUIDERVELD and H. TIMMERMAN, Br. J. Pharmacol. 116 2315-2321 (1995).
9. H. YOKOYAMA, K. ONODERA, K. MAEYAMA, E. SAKURAI, K. IINUMA, R. LEURS, H. TIMMERMAN and T. WATANABE, Eur. J. Pharmacol. 260 23-28 (1994).
10. M.A.M.R. DE ALMEIDA and I. IZQUIERDO, Arch. Int. Pharmacodyn. 283 193-198 (1986).
11. K. TASAKA, New Advances in Histamine Research. K. Tasaka (ed), 27-68, Springer-Verlag, Tokyo (1994).
12. S. MIYAZAKI, M. IMAIZUMI and K. ONODERA, Life Sci. 56 1563-1570 (1995).
13. X.A. ALVAREZ, A. FRANCO, L. FRENÁNDEZ-NOVOA and R. CACABELOS, Agents Actions 38 C263-C265 (1993).
14. S. MIYAZAKI, M. IMAIZUMI and K. ONODERA, Life Sci. 57 2137-2144 (1995).
15. S. MIYAZAKI, M. IMAIZUMI and K. ONODERA, Meth. Find. Exp. Clin. Pharmacol. 17 653-658 (1995).
16. M. GARBARG, M.D. TRUNG TUONG, C. GROS and J.C. SCHWARTZ, Eur. J. Pharmacol. 164 1-11 (1989).
17. E. SCHLICKER, B. MALINOWSKA, M. KATHMAN and M. GÖTHERT, Fundam. Clin. Pharmacol. 8 128-137 (1994).
18. K. FINK, E. SCHLICKER, A. NEISE and M. GÖTHERT, Naunyn-Schmiederberg's Arch. Pharmacol. 342 513-519 (1990).
19. J. CLAPHAM and G.J. KILPATRICK, Br. J. Pharmacol. 107 919-923 (1992).
20. E. SCHLICKER, K. FINK, M. HINTERTHANER and M. GÖTHERT, Naunyn-Schmiederberg's Arch. Pharmacol. 340 633-638 (1989).
21. E. SCHLICKER, K. FINK, M. DETZNER and M. GÖTHERT, J. Neural. Transm. 93 1-10 (1993).
22. K. ONODERA, K. MAEYAMA and T. WATANABE, Jpn. J. Pharmacol. 47 323-326 (1988).
23. S. MIYAZAKI, M. IMAIZUMI and H. MACHIDA, Pharmacol. Biochem. Behav. 49 471-475 (1994).
24. R. OISHI, Y. ITOH, M. NISHIBORI and K. SAEKI, J. Neurochem. 52 1388-1392 (1989).
25. S.K. BHATTACHARYA Eur. J. Pharmacol. 183 925 (1990).
26. E. GIACOBINI, Prog. Brain Res. 98 447-454 (1993).
27. A.G. KARCZMAR, Prog. Neuro-Psychopharmacol. Biol. Psychiat. 19 187-211 (1995).
28. T. MOCHIZUKI, K. OKAKURA-MOCHIZUKI, A. HORII, Y. YAMAMOTO and A. YAMATODANI, J Neurochem. 62 2275-2282 (1994),
29. A. KHATEB, P. FORT, A. PEGNA, B.E. JONES and M. MÜHLETHALER, Neurosci. 69 495-506 (1995).
30. N. GORELOVA and P.B. REINER, J. Neurophysiol. 75 707-714 (1996).
31. S. MIYAZAKI, M. IMAIZUMI and K. ONODERA, Meth. Find. Exp. Clin. Pharmacol. 17 (suppl. C), 57-63 (1995).
32. A.E. FLECKENSTEIN, K.J. LOOKINGLAND and K.E. MOORE, Brain Res. 638 243-247 (1994).
33. D.M. COMPTON, K.M. DIETRICH, J.S. SMITH and K. DAVIS, Neuroreport 7 177-182 (1995).